Clinical Edge Journal Scan

Key clinical point: The risk for late-onset psoriatic arthritis (PsA) was higher in women who attained early natural menopause and had shorter reproductive years.

Major finding: The risk for incident PsA reduced by 46% and 34% in women who reached natural menopause at ≥55 vs <45 years of age and had a reproductive lifespan of ≥38 vs <38 years, respectively (P ≤ .006 for all). The partial population-attributable risk estimated that approximately 1/5of late-onset PsA incidences could be prevented if women went through menopause after the age of 55 years.

Study details: This prospective cohort study included postmenopausal women without psoriatic diseases from the UK Biobank, who were investigated for incident psoriasis (n = 139,572) or PsA (n = 142,329).

Disclosures: This study was supported by the National Natural Science Foundation of China and the Huxiang Youth Talent Supporting Program of Hunan. The authors declared no conflicts of interest.

Source: Xiao Y et al. Age at natural menopause, reproductive lifespan and the risk of late-onset psoriasis and psoriatic arthritis in women: A prospective cohort study. J Invest Dermatol. 2023 (Dec 9). doi: 10.1016/j.jid.2023.11.010

Key clinical point: The risk for late-onset psoriatic arthritis (PsA) was higher in women who attained early natural menopause and had shorter reproductive years.

Major finding: The risk for incident PsA reduced by 46% and 34% in women who reached natural menopause at ≥55 vs <45 years of age and had a reproductive lifespan of ≥38 vs <38 years, respectively (P ≤ .006 for all). The partial population-attributable risk estimated that approximately 1/5of late-onset PsA incidences could be prevented if women went through menopause after the age of 55 years.

Study details: This prospective cohort study included postmenopausal women without psoriatic diseases from the UK Biobank, who were investigated for incident psoriasis (n = 139,572) or PsA (n = 142,329).

Disclosures: This study was supported by the National Natural Science Foundation of China and the Huxiang Youth Talent Supporting Program of Hunan. The authors declared no conflicts of interest.

Source: Xiao Y et al. Age at natural menopause, reproductive lifespan and the risk of late-onset psoriasis and psoriatic arthritis in women: A prospective cohort study. J Invest Dermatol. 2023 (Dec 9). doi: 10.1016/j.jid.2023.11.010

Key clinical point: The risk for late-onset psoriatic arthritis (PsA) was higher in women who attained early natural menopause and had shorter reproductive years.

Major finding: The risk for incident PsA reduced by 46% and 34% in women who reached natural menopause at ≥55 vs <45 years of age and had a reproductive lifespan of ≥38 vs <38 years, respectively (P ≤ .006 for all). The partial population-attributable risk estimated that approximately 1/5of late-onset PsA incidences could be prevented if women went through menopause after the age of 55 years.

Study details: This prospective cohort study included postmenopausal women without psoriatic diseases from the UK Biobank, who were investigated for incident psoriasis (n = 139,572) or PsA (n = 142,329).

Disclosures: This study was supported by the National Natural Science Foundation of China and the Huxiang Youth Talent Supporting Program of Hunan. The authors declared no conflicts of interest.

Source: Xiao Y et al. Age at natural menopause, reproductive lifespan and the risk of late-onset psoriasis and psoriatic arthritis in women: A prospective cohort study. J Invest Dermatol. 2023 (Dec 9). doi: 10.1016/j.jid.2023.11.010

Key clinical point: Poor sleep quality was a very common phenomenon in patients with psoriatic arthritis (PsA) and associated with increased disease activity and higher levels of pain, fatigue, anxiety, and depression.

Major finding: A majority (63%) of patients with PsA experienced poor sleep quality, with factors like higher Disease Activity Index for PsA scores, pain, fatigue, anxiety, and depression (P < .01 for all) associated with poorer sleep quality. Patients with vs without fibromyalgia also reported poorer sleep quality (P < .001).

Study details: Findings are from a single-center cross-sectional study that included 247 patients with PsA.

Disclosures: This study received medical writing/editorial assistance from the Spanish Foundation of Rheumatology. The authors declared no conflicts of interest.

Source: Toledano E et al. SLEEP quality in patients with psoriatic arthritis and its relationship with disease activity and comorbidities: A cross-sectional study. Sci Rep. 2023;13:22927 (Dec 21). doi: 10.1038/s41598-023-48723-z

Key clinical point: Poor sleep quality was a very common phenomenon in patients with psoriatic arthritis (PsA) and associated with increased disease activity and higher levels of pain, fatigue, anxiety, and depression.

Major finding: A majority (63%) of patients with PsA experienced poor sleep quality, with factors like higher Disease Activity Index for PsA scores, pain, fatigue, anxiety, and depression (P < .01 for all) associated with poorer sleep quality. Patients with vs without fibromyalgia also reported poorer sleep quality (P < .001).

Study details: Findings are from a single-center cross-sectional study that included 247 patients with PsA.

Disclosures: This study received medical writing/editorial assistance from the Spanish Foundation of Rheumatology. The authors declared no conflicts of interest.

Source: Toledano E et al. SLEEP quality in patients with psoriatic arthritis and its relationship with disease activity and comorbidities: A cross-sectional study. Sci Rep. 2023;13:22927 (Dec 21). doi: 10.1038/s41598-023-48723-z

Key clinical point: Poor sleep quality was a very common phenomenon in patients with psoriatic arthritis (PsA) and associated with increased disease activity and higher levels of pain, fatigue, anxiety, and depression.

Major finding: A majority (63%) of patients with PsA experienced poor sleep quality, with factors like higher Disease Activity Index for PsA scores, pain, fatigue, anxiety, and depression (P < .01 for all) associated with poorer sleep quality. Patients with vs without fibromyalgia also reported poorer sleep quality (P < .001).

Study details: Findings are from a single-center cross-sectional study that included 247 patients with PsA.

Disclosures: This study received medical writing/editorial assistance from the Spanish Foundation of Rheumatology. The authors declared no conflicts of interest.

Source: Toledano E et al. SLEEP quality in patients with psoriatic arthritis and its relationship with disease activity and comorbidities: A cross-sectional study. Sci Rep. 2023;13:22927 (Dec 21). doi: 10.1038/s41598-023-48723-z

Key clinical point: Adult patients with psoriatic arthritis (PsA) who received biologics, such as interleukin (IL)-12/23, IL-23, and IL-17 inhibitors, or small molecules, such as Janus kinase inhibitors, reported a risk for melanoma and nonmelanoma skin cancer (NMSC).

Major finding: In patients with PsA, the incidence rate of melanoma was 0.09 (95% CI 0.04-0.19) events per 100 patient years (PY) whereas that of NMSC was 0.47 (95% CI 0.28-0.81) events per 100 PY.

Study details: Findings are from a meta-analysis of 19 studies that included 13,739 patients with psoriasis and PsA who were treated with biologics or small molecules tested against an active or placebo comparator.

Disclosures: This study was funded by a research grant from Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Kraków, Poland. P Brzewski declared receiving honoraria or consultation fees from various sources.

Source: Krzysztofik M et al. Risk of melanoma and nonmelanoma skin cancer in patients with psoriasis and psoriatic arthritis treated with targeted therapies: A systematic review and meta-analysis. Pharmaceuticals. 2023;17(1):14 (Dec 21). doi: 10.3390/ph17010014

Key clinical point: Adult patients with psoriatic arthritis (PsA) who received biologics, such as interleukin (IL)-12/23, IL-23, and IL-17 inhibitors, or small molecules, such as Janus kinase inhibitors, reported a risk for melanoma and nonmelanoma skin cancer (NMSC).

Major finding: In patients with PsA, the incidence rate of melanoma was 0.09 (95% CI 0.04-0.19) events per 100 patient years (PY) whereas that of NMSC was 0.47 (95% CI 0.28-0.81) events per 100 PY.

Study details: Findings are from a meta-analysis of 19 studies that included 13,739 patients with psoriasis and PsA who were treated with biologics or small molecules tested against an active or placebo comparator.

Disclosures: This study was funded by a research grant from Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Kraków, Poland. P Brzewski declared receiving honoraria or consultation fees from various sources.

Source: Krzysztofik M et al. Risk of melanoma and nonmelanoma skin cancer in patients with psoriasis and psoriatic arthritis treated with targeted therapies: A systematic review and meta-analysis. Pharmaceuticals. 2023;17(1):14 (Dec 21). doi: 10.3390/ph17010014

Key clinical point: Adult patients with psoriatic arthritis (PsA) who received biologics, such as interleukin (IL)-12/23, IL-23, and IL-17 inhibitors, or small molecules, such as Janus kinase inhibitors, reported a risk for melanoma and nonmelanoma skin cancer (NMSC).

Major finding: In patients with PsA, the incidence rate of melanoma was 0.09 (95% CI 0.04-0.19) events per 100 patient years (PY) whereas that of NMSC was 0.47 (95% CI 0.28-0.81) events per 100 PY.

Study details: Findings are from a meta-analysis of 19 studies that included 13,739 patients with psoriasis and PsA who were treated with biologics or small molecules tested against an active or placebo comparator.

Disclosures: This study was funded by a research grant from Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Kraków, Poland. P Brzewski declared receiving honoraria or consultation fees from various sources.

Source: Krzysztofik M et al. Risk of melanoma and nonmelanoma skin cancer in patients with psoriasis and psoriatic arthritis treated with targeted therapies: A systematic review and meta-analysis. Pharmaceuticals. 2023;17(1):14 (Dec 21). doi: 10.3390/ph17010014

Key clinical point: In pediatric patients, psoriasis vs psoriatic arthritis (PsA) was associated with greater body surface area (BSA) involvement particularly in the extremities, scalp, trunk, genitals, face, skin folds, and nails.

Major finding: The median BSA affected by psoriasis was higher in patients with psoriasis vs PsA (19.7% vs 6.1%; P = .029), with significantly greater disease distribution observed in extremities (75% vs 24%), scalp (61% vs 28%), trunk (58% vs 10%), and genitals (38% vs 10%; P < .05 for all).

Study details: Findings are from a retrospective case-control study that included pediatric patients (age < 18 years) with psoriasis (n = 64) or PsA (n = 29) who were matched by age and sex.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Ollech A et al. Pediatric psoriasis with or without arthritis: Does it make a difference? J Clin Med. 2023;13(1):242 (Dec 31). doi: 10.3390/jcm13010242

Key clinical point: In pediatric patients, psoriasis vs psoriatic arthritis (PsA) was associated with greater body surface area (BSA) involvement particularly in the extremities, scalp, trunk, genitals, face, skin folds, and nails.

Major finding: The median BSA affected by psoriasis was higher in patients with psoriasis vs PsA (19.7% vs 6.1%; P = .029), with significantly greater disease distribution observed in extremities (75% vs 24%), scalp (61% vs 28%), trunk (58% vs 10%), and genitals (38% vs 10%; P < .05 for all).

Study details: Findings are from a retrospective case-control study that included pediatric patients (age < 18 years) with psoriasis (n = 64) or PsA (n = 29) who were matched by age and sex.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Ollech A et al. Pediatric psoriasis with or without arthritis: Does it make a difference? J Clin Med. 2023;13(1):242 (Dec 31). doi: 10.3390/jcm13010242

Key clinical point: In pediatric patients, psoriasis vs psoriatic arthritis (PsA) was associated with greater body surface area (BSA) involvement particularly in the extremities, scalp, trunk, genitals, face, skin folds, and nails.

Major finding: The median BSA affected by psoriasis was higher in patients with psoriasis vs PsA (19.7% vs 6.1%; P = .029), with significantly greater disease distribution observed in extremities (75% vs 24%), scalp (61% vs 28%), trunk (58% vs 10%), and genitals (38% vs 10%; P < .05 for all).

Study details: Findings are from a retrospective case-control study that included pediatric patients (age < 18 years) with psoriasis (n = 64) or PsA (n = 29) who were matched by age and sex.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Ollech A et al. Pediatric psoriasis with or without arthritis: Does it make a difference? J Clin Med. 2023;13(1):242 (Dec 31). doi: 10.3390/jcm13010242

Key clinical point: The risk for uveitis was increased by more than double in patients with psoriatic arthritis (PsA), with past uveitis events and etanercept treatment being significant risk factors.

Major finding: The risk for uveitis was higher in patients with PsA vs matched control individuals without PsA (adjusted hazard ratio 2.38; 95% CI 1.80-3.15). Among patients with PsA, past events of uveitis (adjusted odds ratio [aOR] 136.4; 95% CI 27.38-679.88) and treatment with etanercept (aOR 2.57; 95% CI 1.45-4.57) were associated with an increased risk for uveitis.

Study details: This retrospective matched cohort study included 6147 patients with newly diagnosed PsA and 23,999 matched control individuals without PsA.

Disclosures: This study did not disclose the funding source. The authors declared no conflicts of interest.

Source: Hijazi N et al. The risk factors for uveitis among psoriatic arthritis patients: A population-based cohort study. Clin Rheumatol. 2023 (Dec 11). doi: 10.1007/s10067-023-06834-y

Key clinical point: The risk for uveitis was increased by more than double in patients with psoriatic arthritis (PsA), with past uveitis events and etanercept treatment being significant risk factors.

Major finding: The risk for uveitis was higher in patients with PsA vs matched control individuals without PsA (adjusted hazard ratio 2.38; 95% CI 1.80-3.15). Among patients with PsA, past events of uveitis (adjusted odds ratio [aOR] 136.4; 95% CI 27.38-679.88) and treatment with etanercept (aOR 2.57; 95% CI 1.45-4.57) were associated with an increased risk for uveitis.

Study details: This retrospective matched cohort study included 6147 patients with newly diagnosed PsA and 23,999 matched control individuals without PsA.

Disclosures: This study did not disclose the funding source. The authors declared no conflicts of interest.

Source: Hijazi N et al. The risk factors for uveitis among psoriatic arthritis patients: A population-based cohort study. Clin Rheumatol. 2023 (Dec 11). doi: 10.1007/s10067-023-06834-y

Key clinical point: The risk for uveitis was increased by more than double in patients with psoriatic arthritis (PsA), with past uveitis events and etanercept treatment being significant risk factors.

Major finding: The risk for uveitis was higher in patients with PsA vs matched control individuals without PsA (adjusted hazard ratio 2.38; 95% CI 1.80-3.15). Among patients with PsA, past events of uveitis (adjusted odds ratio [aOR] 136.4; 95% CI 27.38-679.88) and treatment with etanercept (aOR 2.57; 95% CI 1.45-4.57) were associated with an increased risk for uveitis.

Study details: This retrospective matched cohort study included 6147 patients with newly diagnosed PsA and 23,999 matched control individuals without PsA.

Disclosures: This study did not disclose the funding source. The authors declared no conflicts of interest.

Source: Hijazi N et al. The risk factors for uveitis among psoriatic arthritis patients: A population-based cohort study. Clin Rheumatol. 2023 (Dec 11). doi: 10.1007/s10067-023-06834-y

Key clinical point: Functional training (FT) and resistance exercise (RE) improved functional capacity, functional status, disease activity, and muscle strength to a comparable extent in patients with psoriatic arthritis (PsA).

Major finding: FT and RE led to similar improvements in functional capacity measured by the Bath Ankylosing Spondylitis Functional Index (P = .919), functional status measured by the Health Assessment Questionnaire for the Spondyloarthropathies (P = 0.932), disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (P = .700), and muscle strength in patients with PsA. No adverse event occurred in either group.

Study details: Findings are from a 12-week, single-blind trial that included 41 patients with PsA who were randomly assigned to undergo FT with elastic bands or RE with weight machines.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Silva DR et al. Effectiveness of functional training versus resistance exercise in patients with psoriatic arthritis: Randomized controlled trial. Adv Rheumatol. 2023;63:58. (Dec 13). doi: 10.1186/s42358-023-00342-y

Key clinical point: Functional training (FT) and resistance exercise (RE) improved functional capacity, functional status, disease activity, and muscle strength to a comparable extent in patients with psoriatic arthritis (PsA).

Major finding: FT and RE led to similar improvements in functional capacity measured by the Bath Ankylosing Spondylitis Functional Index (P = .919), functional status measured by the Health Assessment Questionnaire for the Spondyloarthropathies (P = 0.932), disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (P = .700), and muscle strength in patients with PsA. No adverse event occurred in either group.

Study details: Findings are from a 12-week, single-blind trial that included 41 patients with PsA who were randomly assigned to undergo FT with elastic bands or RE with weight machines.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Silva DR et al. Effectiveness of functional training versus resistance exercise in patients with psoriatic arthritis: Randomized controlled trial. Adv Rheumatol. 2023;63:58. (Dec 13). doi: 10.1186/s42358-023-00342-y

Key clinical point: Functional training (FT) and resistance exercise (RE) improved functional capacity, functional status, disease activity, and muscle strength to a comparable extent in patients with psoriatic arthritis (PsA).

Major finding: FT and RE led to similar improvements in functional capacity measured by the Bath Ankylosing Spondylitis Functional Index (P = .919), functional status measured by the Health Assessment Questionnaire for the Spondyloarthropathies (P = 0.932), disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (P = .700), and muscle strength in patients with PsA. No adverse event occurred in either group.

Study details: Findings are from a 12-week, single-blind trial that included 41 patients with PsA who were randomly assigned to undergo FT with elastic bands or RE with weight machines.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Silva DR et al. Effectiveness of functional training versus resistance exercise in patients with psoriatic arthritis: Randomized controlled trial. Adv Rheumatol. 2023;63:58. (Dec 13). doi: 10.1186/s42358-023-00342-y

Key clinical point: Adults with pre-existing psoriatic arthritis (PsA) who underwent surgery for lumbar degenerative disease (LDD) faced increased odds of unfavorable discharge and venous thromboembolism (VTE) events compared with those without PsA.

Major finding: A diagnosis of PsA in patients who underwent LDD surgery increased the odds of unfavorable discharge by 26% (adjusted odds ratio [aOR] 1.26; 95% CI 1.03-1.55) and nearly doubled the risk for VTE (aOR 1.99; 95% CI 1.05-3.75).

Study details: This population-based retrospective study included 467,814 patients (age ≥ 20 years) who underwent surgery for LDD, of whom 883 patients had pre-existing PsA and were matched to 8830 patients without PsA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Chen MY et al. Psoriatic arthritis increases the risk of venous thromboembolism following degenerative lumbar spine surgery: An analysis of U.S. Nationwide Inpatient Sample 2005–2018. Heliyon. 2023;10(1):E23613 (Dec 12). doi: 10.1016/j.heliyon.2023.e23613

Key clinical point: Adults with pre-existing psoriatic arthritis (PsA) who underwent surgery for lumbar degenerative disease (LDD) faced increased odds of unfavorable discharge and venous thromboembolism (VTE) events compared with those without PsA.

Major finding: A diagnosis of PsA in patients who underwent LDD surgery increased the odds of unfavorable discharge by 26% (adjusted odds ratio [aOR] 1.26; 95% CI 1.03-1.55) and nearly doubled the risk for VTE (aOR 1.99; 95% CI 1.05-3.75).

Study details: This population-based retrospective study included 467,814 patients (age ≥ 20 years) who underwent surgery for LDD, of whom 883 patients had pre-existing PsA and were matched to 8830 patients without PsA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Chen MY et al. Psoriatic arthritis increases the risk of venous thromboembolism following degenerative lumbar spine surgery: An analysis of U.S. Nationwide Inpatient Sample 2005–2018. Heliyon. 2023;10(1):E23613 (Dec 12). doi: 10.1016/j.heliyon.2023.e23613

Key clinical point: Adults with pre-existing psoriatic arthritis (PsA) who underwent surgery for lumbar degenerative disease (LDD) faced increased odds of unfavorable discharge and venous thromboembolism (VTE) events compared with those without PsA.

Major finding: A diagnosis of PsA in patients who underwent LDD surgery increased the odds of unfavorable discharge by 26% (adjusted odds ratio [aOR] 1.26; 95% CI 1.03-1.55) and nearly doubled the risk for VTE (aOR 1.99; 95% CI 1.05-3.75).

Study details: This population-based retrospective study included 467,814 patients (age ≥ 20 years) who underwent surgery for LDD, of whom 883 patients had pre-existing PsA and were matched to 8830 patients without PsA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Chen MY et al. Psoriatic arthritis increases the risk of venous thromboembolism following degenerative lumbar spine surgery: An analysis of U.S. Nationwide Inpatient Sample 2005–2018. Heliyon. 2023;10(1):E23613 (Dec 12). doi: 10.1016/j.heliyon.2023.e23613

Key clinical point: Female patients with psoriatic arthritis (PsA) who received tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) showed lower treatment persistence than male patients with PsA who received the same therapeutic class of drugs.

Major finding: Women demonstrated 20%-40% lower treatment persistence rates than men for TNFi (adjusted hazard ratio [aHR] 1.4; 99% CI 1.3-1.5) and IL-17i (aHR 1.2; 99% CI 1.1-1.3) therapies; however, the treatment persistence between both sexes was comparable for IL12/23i (aHR 1.1; 99% CI 0.9-1.3), IL23i (aHR 1.1; 99% CI 0.7-1.5), and Janus kinase inhibitor (aHR 1.2; 99% CI 0.9-1.6) therapies.

Study details: This nationwide cohort study included 14,778 patients with PsA who were new users of targeted therapies, of whom 57% were women and 43% were men.

Disclosures: This study did not receive any specific grant. Two authors declared receiving subsidy or consulting fees from or being an investigator for various pharmaceutical companies. Other authors declared no conflicts of interest.

Source: Pina Vegas L et al. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: A cohort study of 14 778 patients from the French health insurance database (SNDS). RMD Open. 2023;9:e003570 (Dec 19). doi: 10.1136/rmdopen-2023-003570

Key clinical point: Female patients with psoriatic arthritis (PsA) who received tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) showed lower treatment persistence than male patients with PsA who received the same therapeutic class of drugs.

Major finding: Women demonstrated 20%-40% lower treatment persistence rates than men for TNFi (adjusted hazard ratio [aHR] 1.4; 99% CI 1.3-1.5) and IL-17i (aHR 1.2; 99% CI 1.1-1.3) therapies; however, the treatment persistence between both sexes was comparable for IL12/23i (aHR 1.1; 99% CI 0.9-1.3), IL23i (aHR 1.1; 99% CI 0.7-1.5), and Janus kinase inhibitor (aHR 1.2; 99% CI 0.9-1.6) therapies.

Study details: This nationwide cohort study included 14,778 patients with PsA who were new users of targeted therapies, of whom 57% were women and 43% were men.

Disclosures: This study did not receive any specific grant. Two authors declared receiving subsidy or consulting fees from or being an investigator for various pharmaceutical companies. Other authors declared no conflicts of interest.

Source: Pina Vegas L et al. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: A cohort study of 14 778 patients from the French health insurance database (SNDS). RMD Open. 2023;9:e003570 (Dec 19). doi: 10.1136/rmdopen-2023-003570

Key clinical point: Female patients with psoriatic arthritis (PsA) who received tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) showed lower treatment persistence than male patients with PsA who received the same therapeutic class of drugs.

Major finding: Women demonstrated 20%-40% lower treatment persistence rates than men for TNFi (adjusted hazard ratio [aHR] 1.4; 99% CI 1.3-1.5) and IL-17i (aHR 1.2; 99% CI 1.1-1.3) therapies; however, the treatment persistence between both sexes was comparable for IL12/23i (aHR 1.1; 99% CI 0.9-1.3), IL23i (aHR 1.1; 99% CI 0.7-1.5), and Janus kinase inhibitor (aHR 1.2; 99% CI 0.9-1.6) therapies.

Study details: This nationwide cohort study included 14,778 patients with PsA who were new users of targeted therapies, of whom 57% were women and 43% were men.

Disclosures: This study did not receive any specific grant. Two authors declared receiving subsidy or consulting fees from or being an investigator for various pharmaceutical companies. Other authors declared no conflicts of interest.

Source: Pina Vegas L et al. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: A cohort study of 14 778 patients from the French health insurance database (SNDS). RMD Open. 2023;9:e003570 (Dec 19). doi: 10.1136/rmdopen-2023-003570

Key clinical point: Although Psoriatic Arthritis Impact of Disease questionnaire-12 items (PsAID-12) scores were higher in patients with psoriatic arthritis (PsA) who did vs did not have a treatment escalation, physicians relied more on their assessment of disease activity while making treatment-related decisions.

Major finding: Higher mean PsAID-12 score correlated with higher odds of treatment escalation in patients with PsA (odds ratio [OR] 1.58; P < .0001), whereas physician’s assessment of disease activity had the most significant impact on likelihood of treatment escalation (OR 2.68; P < .0001). Longer disease duration, treatment with nonbiologics, and a higher swollen joint count also increased the odds for treatment escalation.

Study details: Findings are from a cross-sectional analysis (the ASSIST study) that included 503 patients with PsA (age ≥ 18 years), of whom 160 patients underwent treatment escalation.

Disclosures: This study was funded by Amgen, and the National Institute for Health Research Oxford Biomedical Research Centre. Several authors declared receiving grants, honoraria, consultancy fees, or travel support from or having ties with various sources, including Amgen.

Source: Coyle C et al. How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology (Oxford). 2024 (Jan 8). doi: 10.1093/rheumatology/kead679

Key clinical point: Although Psoriatic Arthritis Impact of Disease questionnaire-12 items (PsAID-12) scores were higher in patients with psoriatic arthritis (PsA) who did vs did not have a treatment escalation, physicians relied more on their assessment of disease activity while making treatment-related decisions.

Major finding: Higher mean PsAID-12 score correlated with higher odds of treatment escalation in patients with PsA (odds ratio [OR] 1.58; P < .0001), whereas physician’s assessment of disease activity had the most significant impact on likelihood of treatment escalation (OR 2.68; P < .0001). Longer disease duration, treatment with nonbiologics, and a higher swollen joint count also increased the odds for treatment escalation.

Study details: Findings are from a cross-sectional analysis (the ASSIST study) that included 503 patients with PsA (age ≥ 18 years), of whom 160 patients underwent treatment escalation.

Disclosures: This study was funded by Amgen, and the National Institute for Health Research Oxford Biomedical Research Centre. Several authors declared receiving grants, honoraria, consultancy fees, or travel support from or having ties with various sources, including Amgen.

Source: Coyle C et al. How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology (Oxford). 2024 (Jan 8). doi: 10.1093/rheumatology/kead679

Key clinical point: Although Psoriatic Arthritis Impact of Disease questionnaire-12 items (PsAID-12) scores were higher in patients with psoriatic arthritis (PsA) who did vs did not have a treatment escalation, physicians relied more on their assessment of disease activity while making treatment-related decisions.

Major finding: Higher mean PsAID-12 score correlated with higher odds of treatment escalation in patients with PsA (odds ratio [OR] 1.58; P < .0001), whereas physician’s assessment of disease activity had the most significant impact on likelihood of treatment escalation (OR 2.68; P < .0001). Longer disease duration, treatment with nonbiologics, and a higher swollen joint count also increased the odds for treatment escalation.

Study details: Findings are from a cross-sectional analysis (the ASSIST study) that included 503 patients with PsA (age ≥ 18 years), of whom 160 patients underwent treatment escalation.

Disclosures: This study was funded by Amgen, and the National Institute for Health Research Oxford Biomedical Research Centre. Several authors declared receiving grants, honoraria, consultancy fees, or travel support from or having ties with various sources, including Amgen.

Source: Coyle C et al. How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology (Oxford). 2024 (Jan 8). doi: 10.1093/rheumatology/kead679

Key clinical point: Neoadjuvant chemotherapy (NAC) that did vs did not contain cisplatin improved survival in patients with operable triple-negative breast cancer (TNBC), especially those with residual cancer burden (RCB) class II/III, a group that is typically associated with worse prognosis.

Major finding: Patients who did vs did not receive cisplatin-based regimens in the overall population reported significantly improved distant disease-free survival (unadjusted hazard ratio [HR] 0.127; P < .001), especially those in the RCB class II/III group (HR 0.192; P = .013).

Study details: Findings are from a retrospective cohort study including 138 previously untreated patients with stage I-III TNBC who received NAC with (n = 52) or without (n = 86) cisplatin.

Disclosures: This study was supported by a Japan Society for Promotion of Science KAKENHI Grant. Several authors declared receiving grants, consulting fees, or honoraria from, or serving as a members of advisory boards, boards of directors, or as an associate editor for various sources.

Source: Yamaguchi A et al. Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: Propensity score matching and inverse probability of treatment weighting analysis. Breast Cancer Res Treat. 2023 (Dec 21). doi: 10.1007/s10549-023-07163-z

Key clinical point: Neoadjuvant chemotherapy (NAC) that did vs did not contain cisplatin improved survival in patients with operable triple-negative breast cancer (TNBC), especially those with residual cancer burden (RCB) class II/III, a group that is typically associated with worse prognosis.

Major finding: Patients who did vs did not receive cisplatin-based regimens in the overall population reported significantly improved distant disease-free survival (unadjusted hazard ratio [HR] 0.127; P < .001), especially those in the RCB class II/III group (HR 0.192; P = .013).

Study details: Findings are from a retrospective cohort study including 138 previously untreated patients with stage I-III TNBC who received NAC with (n = 52) or without (n = 86) cisplatin.

Disclosures: This study was supported by a Japan Society for Promotion of Science KAKENHI Grant. Several authors declared receiving grants, consulting fees, or honoraria from, or serving as a members of advisory boards, boards of directors, or as an associate editor for various sources.

Source: Yamaguchi A et al. Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: Propensity score matching and inverse probability of treatment weighting analysis. Breast Cancer Res Treat. 2023 (Dec 21). doi: 10.1007/s10549-023-07163-z

Key clinical point: Neoadjuvant chemotherapy (NAC) that did vs did not contain cisplatin improved survival in patients with operable triple-negative breast cancer (TNBC), especially those with residual cancer burden (RCB) class II/III, a group that is typically associated with worse prognosis.

Major finding: Patients who did vs did not receive cisplatin-based regimens in the overall population reported significantly improved distant disease-free survival (unadjusted hazard ratio [HR] 0.127; P < .001), especially those in the RCB class II/III group (HR 0.192; P = .013).

Study details: Findings are from a retrospective cohort study including 138 previously untreated patients with stage I-III TNBC who received NAC with (n = 52) or without (n = 86) cisplatin.

Disclosures: This study was supported by a Japan Society for Promotion of Science KAKENHI Grant. Several authors declared receiving grants, consulting fees, or honoraria from, or serving as a members of advisory boards, boards of directors, or as an associate editor for various sources.

Source: Yamaguchi A et al. Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: Propensity score matching and inverse probability of treatment weighting analysis. Breast Cancer Res Treat. 2023 (Dec 21). doi: 10.1007/s10549-023-07163-z